
Angele Consoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11495574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
2	Missing the forest for the trees? A high rate of motor and language impairments in Disruptive Mood Dysregulation Disorder in a chart review of inpatient adolescents. European Child and Adolescent Psychiatry, 2021, 30, 1579-1590.	4.7	5
3	Psychiatric autoimmune conditions in children and adolescents: Is catatonia a severity marker?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110028.	4.8	11
4	Relevance of Brain 18F-FDG PET Imaging in Probable Seronegative Encephalitis With Catatonia: A Case Report. Frontiers in Psychiatry, 2021, 12, 685711.	2.6	3
5	Education and mental health: good reasons to vaccinate children. Lancet, The, 2021, 398, 387.	13.7	12
6	Effective use of atomoxetine to treat six inpatient youths with disruptive mood dysregulation disorder without attention deficit disorder. CNS Spectrums, 2020, 25, 455-457.	1.2	7
7	High diagnostic value of plasma Niemann-Pick type C biomarkers in adults with selected neurological and/or psychiatric disorders. Journal of Neurology, 2020, 267, 3371-3377.	3.6	8
8	Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Translational Psychiatry, 2019, 9, 274.	4.8	35
9	Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach. Case Reports in Psychiatry, 2019, 2019, 1-12.	0.5	0
10	Suicidal behaviors and irritability in children and adolescents: a systematic review of the nature and mechanisms of the association. European Child and Adolescent Psychiatry, 2019, 28, 667-683.	4.7	37
11	Maternal depression symptoms and internalising problems in the offspring: the role of maternal and family factors. European Child and Adolescent Psychiatry, 2018, 27, 921-932.	4.7	38
12	An overview of medical risk factors for childhood psychosis: Implications for research and treatment. Schizophrenia Research, 2018, 192, 39-49.	2.0	67
13	A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. Schizophrenia Research, 2018, 200, 68-76.	2.0	19
14	Catatonia in children and adolescents: New perspectives. Schizophrenia Research, 2018, 200, 56-67.	2.0	56
15	Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 719-726.	1.3	7
16	Catatonia in Children and Adolescents: AÂHigh Rate of Genetic Conditions. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, 518-525.e1.	0.5	22
17	Disentangling Tourette syndrome heterogeneity through hierarchical ascendant clustering. Developmental Medicine and Child Neurology, 2018, 60, 942-950.	2.1	14
18	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 167-176.	1.3	15

ANGELE CONSOLI

#	Article	IF	CITATIONS
19	Adverse Childhood Experiences Among Inpatient Youths with Severe and Early-Onset Psychiatric Disorders: Prevalence and Clinical Correlates. Child Psychiatry and Human Development, 2017, 48, 248-259.	1.9	24
20	Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD. European Child and Adolescent Psychiatry, 2017, 26, 5-23.	4.7	28
21	Management of Severe Developmental Regression in an Autistic Child with a 1q21.3 Microdeletion and Self-Injurious Blindness. Case Reports in Psychiatry, 2017, 2017, 1-8.	0.5	9
22	Cornelia de Lange and Ehlers-Danlos: comorbidity of two rare syndromes. BMJ Case Reports, 2016, 2016, bcr2015210925.	0.5	9
23	Ecological Momentary Assessment and Smartphone Application Intervention in Adolescents with Substance Use and Comorbid Severe Psychiatric Disorders: Study Protocol. Frontiers in Psychiatry, 2016, 7, 157.	2.6	30
24	Validation of the Pediatric Catatonia Rating Scale (PCRS). Schizophrenia Research, 2016, 176, 378-386.	2.0	42
25	Bipolar Disorder Type 1 in a 17-Year-Old Girl with Wolfram Syndrome. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 750-755.	1.3	6
26	Early interventions for youths at high risk for bipolar disorder: a developmental approach. European Child and Adolescent Psychiatry, 2016, 25, 217-233.	4.7	28
27	Do girls with depressive symptoms exhibit more physical aggression than boys? A cross sectional study in a national adolescent sample. Child and Adolescent Psychiatry and Mental Health, 2015, 9, 41.	2.5	14
28	A Systematic Review of the Evidence for Impaired Cognitive Theory of Mind in Maltreated Children. Frontiers in Psychiatry, 2015, 6, 108.	2.6	33
29	Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): Recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement. Research in Developmental Disabilities, 2015, 38, 242-255.	2.2	71
30	Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia. European Child and Adolescent Psychiatry, 2015, 24, 441-449.	4.7	50
31	Management of Adverse Effects of Second-generation Antipsychotics in Youth. Current Treatment Options in Psychiatry, 2014, 1, 84-105.	1.9	12
32	Diagnostic transition towards schizophrenia in adolescents with severe bipolar disorder type I: An 8-year follow-up study. Schizophrenia Research, 2014, 159, 284-291.	2.0	21
33	Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study. European Child and Adolescent Psychiatry, 2013, 22, 55-62.	4.7	57
34	Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Research in Autism Spectrum Disorders, 2013, 7, 167-175.	1.5	43
35	Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents. Journal of Clinical Psychopharmacology, 2012, 32, 309-316.	1.4	167
36	Medical and developmental risk factors of catatonia in children and adolescents: A prospective case–control study. Schizophrenia Research, 2012, 137, 151-158.	2.0	72

ANGELE CONSOLI

#	Article	IF	CITATIONS
37	Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 15.	2.5	52
38	Psychodynamic-oriented psychological assessment predicts evolution to schizophrenia at 8-year follow-up in adolescents hospitalized for a manic/mixed episode: Interest of an overall subjective rating. Journal of Physiology (Paris), 2010, 104, 257-262.	2.1	15
39	Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia. Journal of Physiology (Paris), 2010, 104, 309-314.	2.1	19
40	Commentary on â€~Pharmacotherapy for anxiety disorders in children and adolescents' with a response from the review authors. Evidence-Based Child Health: A Cochrane Review Journal, 2010, 5, 631-633.	2.0	0
41	Electroconvulsive Therapy in Adolescents With the Catatonia Syndrome. Journal of ECT, 2010, 26, 259-265.	0.6	57
42	Predictors of Placebo Response in Randomized Controlled Trials of Psychotropic Drugs for Children and Adolescents with Internalizing Disorders. Journal of Child and Adolescent Psychopharmacology, 2010, 20, 39-47.	1.3	46
43	Risk factors of acute behavioral regression in psychiatrically hospitalized adolescents with autism. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2010, 19, 100-8.	0.6	17
44	Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents. European Child and Adolescent Psychiatry, 2009, 18, 185-193.	4.7	26
45	Moderate clinical improvement with maintenance ECT in a 17-year-old boy with intractable catatonic schizophrenia. European Child and Adolescent Psychiatry, 2009, 18, 250-254.	4.7	45
46	Association of adolescent catatonia with increased mortality and morbidity: Evidence from a prospective follow-up study. Schizophrenia Research, 2009, 113, 233-240.	2.0	73
47	Medication use in adolescents treated in a French psychiatric setting for acute manic or mixed episode. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2009, 18, 231-8.	0.6	9
48	Does catatonia influence the phenomenology of childhood onset schizophrenia beyond motor symptoms?. Psychiatry Research, 2008, 158, 356-362.	3.3	24
49	Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1393-1398.	4.8	54
50	Plasma Exchange in Patients with Stuporous Catatonia and Systemic Lupus Erythematosus. Psychotherapy and Psychosomatics, 2008, 77, 195-196.	8.8	31
51	Comorbidity with ADHD Decreases Response to Pharmacotherapy in Children and Adolescents with Acute Mania: Evidence from a Metaanalysis. Canadian Journal of Psychiatry, 2007, 52, 323-328.	1.9	40
52	Cotard's syndrome in adolescents and young adults is associated with an increased risk of bipolar disorder. Bipolar Disorders, 2007, 9, 665-668.	1.9	31
53	Treatments in child and adolescent bipolar disorders. European Child and Adolescent Psychiatry, 2007, 16, 187-198.	4.7	32
54	Production of supernatural beliefs during Cotard's syndrome, a rare psychotic depression. Behavioral and Brain Sciences, 2006, 29, 468-470.	0.7	8